PD-L1 tested non-small cell lung carcinoma tissue microarray, single core per case. Pathology Grade, TNM Classification and Clinical Stage, and PD-L1 (Sp623) information available. Replacing LC401a.
- 20 cases of PD-L1 (Sp263) is positive and negative,
Price
$170.00
Catalogue No | RLN401b |
Description | PD-L1 tested non-small cell lung carcinoma tissue microarray, single core per case. Pathology Grade, TNM Classification and Clinical Stage, and PD-L1 (Sp623) information available. Replacing LC401a. |
Species | Human |
Fixative | Formalin |
Total Cases | 40 |
Total Cores | 40 |
Core Diameter | 1.5 mm |
Section Thickness | 5 µm |
Storage | Short term RT; Long term 4ºC |
Usage | For research use only. Designed for Immunohistochemistry (IHC) and In Situ Hybridization (ISH) |
A | LU | LU | LU | LU | LU | LU | LU | LU |
B | LU | LU | LU | LU | LU | LU | LU | LU |
C | LU | LU | LU | LU | LU | LU | LU | LU |
D | LU | LU | LU | LU | LU | LU | LU | LU |
E | LU | LU | LU | LU | LU | LU | LU | LU |
N | N/ |
Showing All Data
No. | Map ID | Age | Sex | Organ | Pathology Diagnosis | Grade | TNM | Stage | Type | PD-L1 (Sp623) |
---|---|---|---|---|---|---|---|---|---|---|
1 | A1 | 63 | M | Lung | Squamous cell carcinoma | 2 | T2N1M0 | IIA | Malignant | TC=50% |
2 | A2 | 54 | M | Lung | Squamous cell carcinoma | 2 | T2N2M0 | IIIA | Malignant | TC=30% |
3 | A3 | 55 | M | Lung | Squamous cell carcinoma | 2 | T2N1M0 | IIA | Malignant | TC=30% |
4 | A4 | 65 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | TC=100% |
5 | A5 | 60 | M | Lung | Squamous cell carcinoma | 2 | T2N2M0 | IIIA | Malignant | TC≥ 50% |
6 | A6 | 57 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | TC=45% |
7 | A7 | 51 | M | Lung | Squamous cell carcinoma | 2 | T3N1M0 | IIIA | Malignant | TC≥25% |
8 | A8 | 61 | M | Lung | Squamous cell carcinoma with necrosis | 2 | T3N2M0 | IIIB | Malignant | TC=45% |
9 | B1 | 55 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | TC=55% |
10 | B2 | 68 | M | Lung | Squamous cell carcinoma | 2 | T2bN0M0 | IIA | Malignant | TC≥25% |
11 | B3 | 55 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | TC≥85% |
12 | B4 | 64 | M | Lung | Squamous cell carcinoma | 2 | T2N1M0 | IIA | Malignant | TC≥25% |
13 | B5 | 64 | M | Lung | Squamous cell carcinoma | 2 | T3N1M0 | IIIA | Malignant | TC≥85% |
14 | B6 | 58 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | TC≥25% |
15 | B7 | 56 | M | Lung | Squamous cell carcinoma | 3 | T2N0M0 | IB | Malignant | TC=30% |
16 | B8 | 69 | M | Lung | Squamous cell carcinoma | 3 | T2N0M0 | IB | Malignant | TC=80% |
17 | C1 | 70 | M | Lung | Squamous cell carcinoma | 3 | T2aN0M0 | IB | Malignant | TC≥25% |
18 | C2 | 58 | M | Lung | Squamous cell carcinoma | 3 | T2N1M0 | IIA | Malignant | TC≥25% |
19 | C3 | 60 | M | Lung | Squamous cell carcinoma | 3 | T3N1M0 | IIIA | Malignant | TC≥25% |
20 | C4 | 52 | M | Lung | Squamous cell carcinoma | 3 | T3N2M0 | IIIB | Malignant | TC=30% |
21 | C5 | 54 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
22 | C6 | 57 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
23 | C7 | 36 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
24 | C8 | 42 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
25 | D1 | 65 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
26 | D2 | 48 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
27 | D3 | 52 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
28 | D4 | 64 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
29 | D5 | 58 | M | Lung | Squamous cell carcinoma | 2 | T2N0M0 | IB | Malignant | - |
30 | D6 | 49 | M | Lung | Squamous cell carcinoma | 3 | T2N1M0 | IIA | Malignant | - |
31 | D7 | 50 | F | Lung | Squamous cell carcinoma | 3 | T3N3M0 | IIIC | Malignant | - |
32 | D8 | 57 | M | Lung | Squamous cell carcinoma | 3 | T3N0M0 | IIB | Malignant | - |
33 | E1 | 54 | M | Lung | Squamous cell carcinoma | 3 | T2N0M0 | IB | Malignant | - |
34 | E2 | 64 | M | Lung | Squamous cell carcinoma | 3 | T2N2M0 | IIIA | Malignant | - |
35 | E3 | 62 | M | Lung | Squamous cell carcinoma | 3 | T3N1M0 | IIIA | Malignant | - |
36 | E4 | 62 | F | Lung | Squamous cell carcinoma | * | T2N0M0 | IB | Malignant | - |
37 | E5 | 58 | M | Lung | Squamous cell carcinoma | 3 | T2N0M0 | IB | Malignant | - |
38 | E6 | 43 | M | Lung | Squamous cell carcinoma | 3 | T3N1M0 | IIIA | Malignant | - |
39 | E7 | 70 | M | Lung | Squamous cell carcinoma | 3 | T2N0M0 | IB | Malignant | - |
40 | E8 | 46 | M | Lung | Squamous cell carcinoma with necrosis | 3 | T3N1M0 | IIIA | Malignant | - |
N/A | N/A | N/A | N/A | N/A | _kidney cancera_Tissue Marker | N/A | N/A | N/A | N/A | N/A |